GeneGo, Inc., a leading provider of software and databases for systems biology, has announced that RNAi Co., Ltd (RCL) has licensed MetaCore for its RNA interference drug discovery efforts.

MetaCore is an integrated platform for the analysis of different types of experimental data in drug discovery. MetaCore applies a proprietary, manually curated, human protein interaction and pathway database to drug discovery. The flexible database architecture enables straightforward integration of in house and third party software and databases. MetaCore also has easy to use software for building, visualization and analysis of tissue specific biological networks with and without experimental data, claims a release from GeneGo.

Tatiana Nikolskaya, president and CSO of GeneGo said, "RCL has built an impressive and unique technology portfolio in the RNA interference area. Their findings are very synergistic with pathway analysis of complex diseases we are working on. We consider this agreement as the first step in long term collaboration in the intersection of these two exciting technologies."

RCL is a biotechnology company in the field of functional genomics based on RNA interference. RCL conducts two types of business.